Baidu
map

Clinica Chimica Acta:土耳其囊性纤维化患者CFTR基因突变和新变异?

2020-08-09 MedSci原创 MedSci原创

囊性纤维化是最常见的由CFTR基因突变引起的常染色体隐性遗传疾病。土耳其患者CFTR突变的频谱和频率表现出一定的异质性。

囊性纤维化是最常见的由CFTR基因突变引起的常染色体隐性遗传疾病。土耳其患者CFTR突变的频谱和频率表现出一定的异质性。

本研究对来自土耳其最大的转诊CF中心Hacettepe大学的604例囊性纤维化患者的CFTR基因突变进行研究。还分析了新变异的影响,并预测致病性综合信息从不同的预测工具。

通过对编码区和外显子/内含子边界的直接测序,突变检出率提高到76.7%。首次被描述10个变异。除T788R外,所有变异均报道为致病性的。

研究表明,对CFTR突变发生频率非常低的患者进行特征分析对于基于突变的治疗是必要的。因为由于突变分布不均,没有一种适合土耳其患者,所以应设计人群特异性基因筛选策略。从新变异的结果中获得的初步数据将为使用从患者获得的样本进行功能分析铺平道路。

这些观察结果将促进新的靶向和个性化治疗的发现和发展。

原始出处:

DidemDayangaç-Erden,Merve Atalay,Mutations of the CFTR gene and novel variants in Turkish patients with cystic fibrosis: 24-years experience

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-03-13 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2020-10-25 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1723341, encodeId=ee1b1e233415e, content=<a href='/topic/show?id=9ac04125417' target=_blank style='color:#2F92EE;'>#土耳其#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41254, encryptionId=9ac04125417, topicName=土耳其)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=581b33444961, createdName=aliceclz, createdTime=Tue Dec 01 06:56:00 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4532, encryptionId=3dbd4532a9, topicName=CFTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=158922650058, createdName=644982816_68283328, createdTime=Thu Nov 12 05:56:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850011, encodeId=7b221850011b4, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 02:56:00 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675933, encodeId=68bf16e593308, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Oct 25 13:56:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006175, encodeId=b6e820061e5dd, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Fri Aug 14 21:56:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668827, encodeId=0a4d166882e9b, content=<a href='/topic/show?id=ba194533c3' target=_blank style='color:#2F92EE;'>#CFTR基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4533, encryptionId=ba194533c3, topicName=CFTR基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ddc26453602, createdName=crystal0571, createdTime=Fri Apr 30 18:56:00 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985921, encodeId=ef27198592107, content=<a href='/topic/show?id=85be581432f' target=_blank style='color:#2F92EE;'>#新变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58143, encryptionId=85be581432f, topicName=新变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Sun Oct 18 03:56:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950312, encodeId=b22619503127c, content=<a href='/topic/show?id=78af453401' target=_blank style='color:#2F92EE;'>#CFTR基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4534, encryptionId=78af453401, topicName=CFTR基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Feb 04 09:56:00 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342722, encodeId=14031342e22fb, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Aug 11 13:56:00 CST 2020, time=2020-08-11, status=1, ipAttribution=)]

相关资讯

Transpl Infect Dis:囊性纤维化患者更易耐受抗病毒药物

药物更昔洛韦,在移植后给予肺移植患者以防止威胁生命的病毒。昔洛韦降低病毒导致的死亡率从34%降低到3至6%。但还是有5%和10%患者感染病毒后能够抵抗该药物。 洛约拉大学医学中心研究发现,发生这样的耐药性可能在囊性纤维化患者中更频繁地。这些患者中发现有在他们的血液中更昔洛韦药物水平不充分,从而使病毒不断复制。这反过来可能会增加突变的发生而导致耐药性。 研究表明,囊性纤维化患者应进行监测,以确保

Baidu
map
Baidu
map
Baidu
map